Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611806 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT00611806: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00611806 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00611806, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Folic Acid
- DIETARY_SUPPLEMENT B12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611806
The ClinicalTrials.gov registry entry for NCT00611806 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00611806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611806 about?
NCT00611806 is a clinical study titled "Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia". This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia.
What is the current status of trial NCT00611806?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2007-12. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00611806?
The interventions under investigation include: Placebo (OTHER), Folic Acid (DIETARY_SUPPLEMENT), B12 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00611806?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.